MetaCap

Greenwich LifeSciences (GLSI) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Greenwich LifeSciences (GLSI) has outperformed Relmada Therapeutics (RLMD) over the past year, gaining 136.2% versus a loss of 38.6%. Over five years, GLSI leads with a -41.8% price change compared with -86.1% for RLMD. Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $279.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GLSI+136.20%RLMD-38.64%
+329%+137%-56%
Nov 21, 20251 yearNov 20, 2026
GLSI-44.75%RLMD-87.15%
+91%-9%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GLSI versus RLMD key metrics
MetricGLSIRLMD
Share price$19.25$2.62
Market cap$282.56M$279.54M
1-day change-2.73%-15.76%
YTD return-8.38%-45.76%
1-year return+136.20%-38.64%
5-year return-41.84%-86.09%
EPS (TTM)$-1.63$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-19.36M$-57.39M
52-week high$34.10$8.00
52-week low$7.78$2.60
Distance from 52-week high-43.55%-67.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+198.70%+310.31%
Average volume160.76K1.45M
Shares outstanding14.68M106.69M
Employees—17
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GLSI has outperformed RLMD by 174.8 percentage points over the past year.

About Greenwich LifeSciences

GLSI stock →

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.

Health Care · Biotechnology: Pharmaceutical Preparations

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

GLSI vs RLMD FAQ

Which is bigger, Greenwich LifeSciences or Relmada Therapeutics?

Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $279.54M for Relmada Therapeutics (RLMD).

Which stock has performed better over the past year, GLSI or RLMD?

GLSI returned +136.20% over the past 12 months, compared with -38.64% for RLMD (price return, excluding dividends). Past performance does not predict future results.

Are Greenwich LifeSciences and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons